Bluebird prices gene therapy at 1.575 mln euros over five years
Bluebird bio Inc on Friday set
a price for its gene therapy, Zynteglo, at 1.575 million euros
($1.78 million) over five years, after winning conditional
approval in Europe this month to treat a rare genetic blood
disorder.
a price for its gene therapy, Zynteglo, at 1.575 million euros
($1.78 million) over five years, after winning conditional
approval in Europe this month to treat a rare genetic blood
disorder.
Posted by Reuters
